Literature DB >> 2889500

Comparison of faecal florae in patients with rheumatoid arthritis and controls.

R Shinebaum1, V C Neumann, E M Cooke, V Wright.   

Abstract

The faecal flora of 25 out-patients with active rheumatoid arthritis (RA) was compared with that of 25 age- and sex-matched controls. A comprehensive survey revealed a significantly higher carriage rate of Clostridium perfringens in the RA population (88%) than controls (48%) (p less than 0.01). Coliform counts also tended to be higher, but there were no other significant differences between patients and controls. When the study was enlarged to include a further 113 RA patients with variable disease activity and a further 38 controls, clostridia were again more frequently carried by those with RA (70%) than controls (45%) (p less than 0.01) and clostridial counts were significantly higher in the patient group (p = 0.006). Moreover, counts in patients with active or moderately active disease were significantly higher than in those with inactive disease (p less than 0.001). These data are consistent with the hypothesis that Cl. perfringens plays a role in triggering or is otherwise associated with disease activity in RA. The findings may be alternatively an effect of the disease or its treatment with, for example, anti-inflammatory drugs.

Entities:  

Mesh:

Year:  1987        PMID: 2889500     DOI: 10.1093/rheumatology/26.5.329

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  15 in total

1.  Food intolerance in rheumatoid arthritis. I. A double blind, controlled trial of the clinical effects of elimination of milk allergens and azo dyes.

Authors:  M A van de Laar; J K van der Korst
Journal:  Ann Rheum Dis       Date:  1992-03       Impact factor: 19.103

Review 2.  Is the gut intrinsically abnormal in rheumatoid arthritis?

Authors:  A Doube; A J Collins
Journal:  Ann Rheum Dis       Date:  1988-08       Impact factor: 19.103

3.  Vegetarian diet for patients with rheumatoid arthritis--status: two years after introduction of the diet.

Authors:  J Kjeldsen-Kragh; M Haugen; C F Borchgrevink; O Førre
Journal:  Clin Rheumatol       Date:  1994-09       Impact factor: 2.980

Review 4.  Altered gut microbiota in RA: implications for treatment.

Authors:  Y Kang; Y Cai; X Zhang; X Kong; J Su
Journal:  Z Rheumatol       Date:  2017-06       Impact factor: 1.372

Review 5.  The role of the microbiome in rheumatic diseases.

Authors:  Nigel Yeoh; Jeremy P Burton; Praema Suppiah; Gregor Reid; Simon Stebbings
Journal:  Curr Rheumatol Rep       Date:  2013-03       Impact factor: 4.592

6.  An uncooked vegan diet shifts the profile of human fecal microflora: computerized analysis of direct stool sample gas-liquid chromatography profiles of bacterial cellular fatty acids.

Authors:  R Peltonen; W H Ling; O Hänninen; E Eerola
Journal:  Appl Environ Microbiol       Date:  1992-11       Impact factor: 4.792

7.  Intestinal permeability in patients with yersinia triggered reactive arthritis.

Authors:  R Lahesmaa-Rantala; K E Magnusson; K Granfors; R Leino; T Sundqvist; A Toivanen
Journal:  Ann Rheum Dis       Date:  1991-02       Impact factor: 19.103

Review 8.  Role of Intestinal Microbiota on Gut Homeostasis and Rheumatoid Arthritis.

Authors:  Mingxin Li; Fang Wang
Journal:  J Immunol Res       Date:  2021-06-04       Impact factor: 4.818

Review 9.  Intestinal Dysbiosis and Rheumatoid Arthritis: A Link between Gut Microbiota and the Pathogenesis of Rheumatoid Arthritis.

Authors:  Gabriel Horta-Baas; María Del Socorro Romero-Figueroa; Alvaro José Montiel-Jarquín; María Luisa Pizano-Zárate; Jaime García-Mena; Ninfa Ramírez-Durán
Journal:  J Immunol Res       Date:  2017-08-30       Impact factor: 4.818

10.  Dietary therapy with Lactobacillus GG, bovine colostrum or bovine immune colostrum in patients with juvenile chronic arthritis: evaluation of effect on gut defence mechanisms.

Authors:  M Malin; P Verronen; H Korhonen; E L Syväoja; S Salminen; H Mykkänen; H Arvilommi; E Eerola; E Isolauri
Journal:  Inflammopharmacology       Date:  1997       Impact factor: 5.093

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.